aEvidence for these therapies comes from studies of individuals with Dravet syndrome, and there is limited evidence for the use of these therapies in other SCN1A-related epilepsies due to loss of function variants. Here, SCN1A is linked to encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.